ARPA-H Holds $1.5 Billion Budget, Bets Big on AI and Longevity
April 5, 2026 · 2 min read
Arthur Griffin
The Advanced Research Projects Agency for Health emerged from the FY2026 budget battle with its $1.5 billion appropriation intact — flat-funded for the third consecutive year despite the White House's request to cut the agency to $945 million. That budget stability, however, masks significant internal turbulence: at least 15 employees were laid off in early February, and several programs in hospital cybersecurity, AI for medical imaging, and preventive care were terminated.
What is growing is ARPA-H's portfolio in chronic disease, longevity science, and clinical AI — areas that align with the administration's "Make America Healthy Again" priorities.
New Programs Worth Watching
ARPA-H has launched 33 programs to date, with several recent additions signaling where the agency is placing its biggest bets. ADVOCATE (Agentic AI-Enabled Cardiovascular Care Transformation) aims to deploy AI agents that can transform how heart disease is diagnosed and managed. PROSPR (PROactive Solutions for Prolonging Resilience) is developing early-detection systems that combine continuous monitoring, home specimen collection, and imaging to catch physiological decline before symptoms appear.
Other active programs include STOMP (Systematic Targeting of MicroPlastics), FRONT (Functional Repair of Neocortical Tissue), and AIR (Autonomous Interventions and Robotics) — each representing the kind of high-risk, high-reward health technology bets that justify ARPA-H's existence.
How to Access ARPA-H Funding
Unlike traditional NIH grants, ARPA-H uses flexible funding mechanisms including cooperative agreements, contracts, and Other Transactions authority. The agency maintains open solicitations through its Innovative Solutions Openings, which allow researchers to pitch ideas outside of named programs. With nearly 150 projects funded across 23 states and three innovation hubs in Dallas, Boston, and the National Capital Region, the agency's geographic reach continues to expand.
For biomedical researchers and health tech startups tracking funding on grantedai.com, ARPA-H represents a distinct opportunity: faster timelines, larger individual awards, and a tolerance for unconventional approaches that the traditional NIH pipeline does not accommodate.
In-depth analysis of ARPA-H funding strategy is available on the Granted blog.